-
AstraZeneca, Compugen in $200M Drug Discovery Tie-up
Compugen, a provider of predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, has entered into an exclusive li...
2018-04-04 17:29 -
FujiFilm Acquires Irvine Scientific from JXTG
JXTG Nippon Oil & Energy Corporation has announced it has agreed to sell Irvine Scientific Sales Company, Inc. and IS Japan Co., Ltd. to FUJIFILM Corp...
2018-04-04 17:29 -
Therapure Biopharma Launches Biologics Division
Therapure Biopharma has launched its plasma products and technology division as Evolve Biologics. Evolve's leadership team consists of chief executiv...
2018-04-04 17:29 -
Rhythm, Takeda Enter Development Agreement
Rhythm Pharmaceuticals has acquired exclusive, worldwide rights from Takeda to develop and commercialize T-3525770 (now RM-853).
2018-04-04 17:29 -
C4X, Indivior Sign License Agreement
C4X Discovery has signed a licensing agreement with Indivior to further develop and commercialize C4XD's oral Orexin-1 receptor antagonist ("C4X3256")...
2018-04-04 17:29 -
EC Approves Alofisel For Complex Perianal Fistulae In Crohn’s Disease
TiGenix NV and Takeda Pharmaceutical Company have announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601,...
2018-04-04 17:10 -
Taking a Standard Prostate Cancer Drug With Food Boosts Impact
By taking a high-cost drug with a low-fat meal–instead of on an empty stomach, as prescribed–prostate cancer patients could decrease their daily dos...
2018-04-04 17:10 -
Astrazeneca’s Lokelma Receives EU Approval
AstraZeneca is a global, science-led biopharmaceutical company, announced that the European Commission has granted marketing authorisation for Lokelma...
2018-04-04 17:06 -
Test for Antibiotic Associated Kidney Damage in Children With CF Identified
New research highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis（CF）.
2018-04-04 17:03 -
Chrys Capital to Buy 10% in Mankind for $350 M
India-bred private equity firm Chrys Capital is set to acquire 10 per cent in fast-growing Mankind Pharmaceuticals for $350 million. GIC of Singapore ...
2018-04-03 17:45
Hot News
- Global MDI/TDI Plants Enter Pe... Jul 23, 2025
- Europe Faces Unprecedented Pet... Jul 23, 2025
- BASF Launches Second Round of ... Jul 24, 2025
- Corning Acquires JA Solar’s $... Jul 30, 2025
- Shiseido Americas Plans Major ... Jul 21, 2025
Related Products
Related Producers
